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ABSTRACT  
International conference on harmonization (ICH) suggested that bridging study is important to extrapolate clinical results. and also  us food and 
drug administration requires Substantial evidences regarding safety. The review explains about different approaches that are necessary for 
obtaining clinical results, various clinical results were performed between similar patient population within same or different regions. 
moreover no criteria on the  evaluation of similarity of clinical results between regions is given .It is important in regulatory submission of new 
drug application .Mainly this review explains about how clinical results are reproducible.  
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INTRODUCTION: 
US food and drug administration (USFDA) requires well 
controlled clinical trials for providing substantial evidences 
and also regarding the safety under investigation. The main 
purpose of requiring these two clinical trials is to assure the 
reproducibility and also to provide information regard in  
generalizability . It can be defined as extension of research 
finding and conclusions. 
The clinical trials can be performed to other similar patient 
population with in same region or from region to region, 
which means drugs to be approved by same region or from 
different regions etc. 
 ICH international conference on Harmonisation 
recommends bridging studies  to generate limited amount of 
clinical data in new region mainly to extrapolate clinical data 
between two regions. For assurance of generalizability, it is 
very essential and necessary to determine whether a clinical 
data providing positive results along with substantial 
evidence. 
This review also introduces concepts of generalizability of 
positive clinical trials is also introduced. In these review 
several methods were discussed for evaluation of 
generalizability which includes Frequentist approach and 
Bayesian approach[1] . 
 
GENERALIZABILITY: 
Clinical trails were to be performed for considering the 
situation, but due to differences in ethnic factors second 
clinical and first clinical results were slightly different. 
Mainly it includes the differences in mean and variance. 
Sometimes both mean variance of primary endpoints too. 
Suppose in first clinical trial if we take old parents and in 
second clinical trail if we choose adults then the two results 
will be different. 
Suppose both 1 and 2 clinical trails of same population then 
reproducibility will be different. So for this the scientist 
named SHAO and CHOW defined about reproducibility  and 
pprobability[3].To access the same clinical results we have to 
use the first clinical data to second one so that the results 
may be same and common. 
FREQUENTIST APPROACH:[2]  
In two parallel group design, may µ1 µ2 be population mean 
difference and σ2 be common population variance of first 
trail  
In case if the second trail population, mean difference can 
change to µ1-µ2 +e and population variance changes to c2 σ2. 
In that c>0 [µ1 -µ2] \σ is signal to noise ratio. 
Then the signal to noise ratio for population difference in 
second trial is  
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                                    | µ1 -µ2 +e |  =  | ∆ ( µ -µ ) 
                             C σ                     σ 
  Where  
 
                     ∆=1+e\ (µ1 -µ2 
                                     C 
It is a measure of change in signal to noise ratio for 
population different patients are randomly assigned for 
treatment group then the power for second trail is : 
1-Tn-2  (t0.975; n-2| ∆Ɵ)+ Tn-2) (t0.975;n-2| ∆Ɵ) 
Tn-2 (∆Ɵ) is non central t-distribution with no degrees of 
freedom and non centrality parameter ∆Ɵ. 
                        
1/n21/n1µ2/ - µ1= 
 
In these x1s and s22.s are sample means variance of first trial 
data base reproducibility, probability in clinical research can 
be obtained with T and replaced by ∆t. 
∆x =1- Tn-2  ( t0.975,n-2| ∆T) + Tn-2 ( t0.975 n-2| ∆t) 
Ggeneralizability, probability, based on approach as outlined 
in entry  
Rreproducibility, probability in clinical research is given by  
∆x =1-Tn-2 (t0.975,n-2) ∆Ɵ 
Values of p∆ can be obtained using 2 and 3 tablets in entry of 
reproducibility and probability in clinical research. 
BAYESIAN APPROACH: [3] 
 Based on approach given by 
Π(δ/ γ2 ,x ) π (γ2 |x) 
ɸ =density function of normal distribution 
T is given by 
π (γ2\x )=f(u) 
We may consider avg p∆=  ʃ p∆π (∆)d∆. 
APPLICATIONS: 
Information about bridging studies can be found in ICH 
GUIDELINES in detail. It is useful in regulatory submission 
for supplement new drug application mmainly in clinical 
development after the investigation drug product has been 
shown to be effective and safe with respect to patient 
populationn.It is often of interest to study how likely the 
clinical result is reproducible in similar but slightly different  
in patient population. 
CONCLUSION: 
It is important to determine whether clinical results can be 
generalized. From patient population to another slight 
different population with in same region. These approaches 
are used for helpful of qualitative analysis of generalizability 
probabilities. Also it is important to determine clinical trail 
that is produced by substantial evidences are also helpful in 
assurance of generalizability. Difference varies in mean 
variance and also both mean and variance of primary 
endpoints, which are used to obtain generalizability in case 
study. Designs with slight common variance on the other 
cases are illustrated. These are generally used for approval of 
new drug product. 
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